Atlas Trials

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Clinical trial NCT04599790 · COMPLETED

Trial details

NCT number
NCT04599790
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma Non-resectable
Start date
2020-10-01
Primary completion
2021-11-29
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.